Aggressive relapsing multiple sclerosis characterized by rapid disability progression.

Area of Science:

• Neurology
• Clinical Trials
• Disease Progression

Background:

• Lack of established criteria for identifying aggressive relapsing multiple sclerosis (RMS) hinders clinical decision-making.
• Aggressive disease in RMS is often characterized by rapid disability progression.

Purpose of the Study:

• To identify patients with relapsing multiple sclerosis (RMS) exhibiting aggressive disease, defined by rapid disability progression.
• To assess the long-term outcomes associated with this definition of aggressive RMS.

Main Methods:

• Retrospective analysis of a 2-year, phase 3, double-blind, placebo-controlled trial involving RMS patients treated with intramuscular interferon beta-1a (IM IFNβ-1a) or placebo.
• Defined aggressive RMS as a ≥2.0-point increase in Expanded Disability Status Scale (EDSS) score to ≥4.0 by study end.
• Calculated the odds ratio for severe long-term disability (EDSS ≥8.0 at 8 years) in aggressive RMS patients versus others.

Main Results:

• Twenty-five RMS patients met the criteria for aggressive disease.
• Fewer patients receiving IM IFNβ-1a met aggressive RMS criteria compared to placebo (7% vs. 22%, p=0.0072).
• Aggressive RMS patients had an 86.4-fold increased odds of severe disability (EDSS ≥8.0) at 8 years (p<0.0001).

Conclusions:

• Defining aggressive relapsing multiple sclerosis (RMS) by rapid EDSS progression effectively identifies patients at higher risk for severe disease.
• This definition aids in predicting long-term outcomes and informs clinical management strategies for RMS.